icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
3m3GqhG06Fz1xemJ